Biotechnology

ImmunityBio

ImmunityBio Director Barry J. Simon Sells 23,033 Shares at $7.18 Avg Price

ImmunityBio presents latest Phase III data for ANKTIVA in lung and bladder cancer at ASCO

ImmunityBio Emphasizes UK NMIBC Patients Support Bladder Preservation at ISPOR 2026

ImmunityBio Presents Data Showing NAI+BCG Outperforms nadofaragene and TAR-200 in Efficacy and Safety

ImmunityBio Presents ANKTIVA Plus BCG Outperforms Competitors with Better Efficacy and Safety at 2026 AUA

ImmunityBio Secures Exclusive US Rights to Tokyo-172 BCG Strain from Japan's BCG Lab

ImmunityBio Secures 5 U.S. Patents for ANKTIVA Plus BCG Combination Through 2035

ImmunityBio Signs Exclusive US Deal with Japan BCG Lab to Boost Supply

ImmunityBio released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 44.21 M (forecast USD 43.94 M), actual EPS USD -0.6162 (forecast USD -0.07)

ImmunityBio to Report Q1 2026 Earnings

ImmunityBio Announces Pancreatic Cancer Clinical Trial

ImmunityBio Launches ANKTIVA in Saudi Arabia

ImmunityBio Reports Q1 2026 Revenue Exceeding Expectations

ImmunityBio Secures $100 Million in Funding for Anktiva Sales Expansion

IBRX Option Market Trading Conditions

ImmunityBio's ANKTIVA Plus BCG Recommended in 2026 NCCN Bladder Cancer Guidelines

ImmunityBio Completes NK Cell Manufacturing Projects, Shares Rise

ImmunityBio Completes Phase 1 Clinical Trial of M-ceNK Cells and ANKTIVA Combination Therapy

ImmunityBio Releases Investor Presentation on Immune Therapy Platform

ImmunityBio Beats Earnings Expectations Despite Share Price Decline

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

LIFE

IBRX

The article highlights US growth companies with high insider ownership, such as ImmunityBio, Li Auto, and Ethos Technologies, noting their potential for substantial earnings growth. It provides an overview of these firms' operations, insider stakes, and financial forecasts, while cautioning that the content is general analysis based on historical data and not financial advice.

Simplywall

Ethos Tech

Uxin

Upstart

On Holding AG

Karman

Duos Tech

Corcept Therap

Astera Labs

AppLovin

Abeona Therap

Li Auto

LI AUTO-W

3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News

StockTitan

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News

IBBQ

LABU

LABD

The Gross Law Firm reminds ImmunityBio, Inc. (NASDAQ: IBRX) shareholders of a lead plaintiff deadline on May 26, 2026, for a class action lawsuit. Shareholders who purchased shares between January 19, 2026, and March 24, 2026, are encouraged to register for potential lead plaintiff appointment due to allegations of misleading statements by the company. Participation in the case incurs no cost.

prnewswire

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Direxion S&P Biotech Bear 3X

09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

SBIO

Rosen Law Firm is reminding investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, of the May 26, 2026, deadline to lead a securities fraud class action lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges misleading statements by the company regarding its product capabilities, leading to investor losses. Interested parties can contact the firm for more information.

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

19:37 ETIBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA flagged misleading claims about its cancer treatment, Anktiva. Following the FDA's warning, IBRX shares plummeted over 21%, resulting in a loss of nearly $2 billion in market capitalization. The lawsuit seeks to represent investors who acquired IBRX securities between January 19 and March 24, 2026. Hagens Berman is investigating claims of intentional misrepresentation by ImmunityBio regarding Anktiva's efficacy.

PR Newswire

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

The Law Offices of Howard G. Smith announces that investors who suffered losses in ImmunityBio, Inc. (IBRX) have the opportunity to lead a securities fraud class action lawsuit. The complaint alleges that the company misled investors about Anktiva's capabilities between January 19, 2026, and March 24, 2026. Interested investors should contact the law firm before May 26, 2026, to participate.

12:00 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News

Health Care Select Sector SPDR

iShares US Pharma

VG Health

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News

ImmunityBio(IBRX.US)

3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News

09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

19:37 ETIBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

12:00 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News